-
Finding new ways to protect patients during chemo
09/26/2016
Newly identified type of lung macrophage protects chemotherapy-treated mice from lethal bacterial pneumonia despite absence of neutrophils.
-
Editing sickle cell disease
08/15/2016
A new gene editing approach eases the effects of sickle cell disease in blood cells isolated from patients.
-
Most teen survivors of childhood cancer are well adjusted
07/18/2016
While most teen cancer survivors are well adjusted, some may benefit from more comprehensive psychological screening to identify and treat symptoms
-
Chemo drug makes multitasking a challenge for some leukemia survivors
06/06/2016
Methotrexate exposure tied to reduced mental flexibility, planning and other executive function skills in long-term survivors of pediatric leukemia.
-
Child life specialists help young patients get ready for radiation treatment
05/18/2016
Child life specialists show support interventions decrease sedation use and cost for radiation therapy.
-
Applied math and supercomputing help smooth transition from lab to clinic
05/10/2016
A modeling approach used lab data to find the optimal drug dose in a successful clinical trial for children with recurrent ependymoma.
-
Targeted antibiotics may help protect bacterial good guys in the gut
05/09/2016
Targeted antibiotic is easier on the gut microbiome; highlights a possible antibiotic drug development strategy
-
Risk factors found for leukemia treatment complication
04/25/2016
Study finds age, ancestry and genetics can influence the risk of pancreatitis, a serious chemo side effect in acute lymphoblastic leukemia patients.
-
Early success for gene therapy against "bubble boy" disease
04/20/2016
Patients with severe combined immunodeficiency (SCID) show unprecedented immune system recovery after receiving gene therapy developed at St. Jude.
-
Problems in cellular cleanup may contribute to lupus
04/20/2016
The most common form of the autoimmune disease lupus may be linked to defects in a cell disposal process called LAP.
-
Cancer immune therapy: A potential new avenue
04/11/2016
T cells do different jobs in the immune system depending on how much c-Myc protein they make, scientists find. What could this mean for immune therapies?
-
Designing an irresistible flu drug
03/14/2016
A promising anti-influenza agent may spark the development of new medicines and combat drug resistance.
-
Brain infections likely cause different problems before and after birth
03/09/2016
Early evidence suggests that infections during pregnancy may alter brain anatomy by driving neuronal proliferation and lead to learning problems.
-
A new way for cells to kill themselves
03/03/2016
When damaged cells don’t die as planned, problems can arise—including cancers. The discovery of a new cell death process may point to new ways to destroy diseased cells.
-
Insights into improving pneumonia vaccines
02/29/2016
One of the deadliest living things on Earth is the pneumococcus bacterium. Insights into how it survives and spreads have profound implications for vaccine strategies.
-
Diagnosing CNS-PNET tumors: Beyond the microscope
02/25/2016
Molecular techniques may beat the microscope for diagnosing CNS-PNET, an aggressive childhood brain tumor.
-
Parental influence extends to drug response
02/15/2016
Researchers demonstrate how differences in inherited genetic makeup can cause problems during leukemia treatment.
-
Clues to precision treatments for a tough childhood leukemia
02/08/2016
Researchers reveal genetic secrets of a high-risk pediatric leukemia called Ph-ALL, and find treatment potential in the drug ruxolitinib.
-
Understanding how brain tumor treatment affects the brain
02/01/2016
An unprecedented study finds that survivors of childhood brain tumors are at risk of memory and intelligence deficits. A key goal? Catch them early.
-
A promising anti-inflammatory drug tames the immune system
01/29/2016
The drug ruxolitinib shows promise in targeting inflammatory reactions in the immune disorder hemophagocytic lymphohistiocyosis (HLH).
-
Where a brain tumor begins
01/27/2016
Research led by a St. Jude scientist has pinpointed likely cells of origin for a common childhood brain tumor, Group 4 medulloblastoma.
Research Highlights
